keyword
MENU ▼
Read by QxMD icon Read
search

Immune modulatory agents

keyword
https://www.readbyqxmd.com/read/28750572/small-molecules-as-therapy-for-uveitis-a-selected-perspective-of-new-and-developing-agents
#1
Uwe Pleyer, Engi Abdel-Hady Algharably, Eugen Feist, Reinhold Kreutz
Intraocular inflammation (uveitis) remains a significant burden of legal blindness. Because of its immune mediated and chronic recurrent nature, common therapy includes corticosteroids, disease-modifying anti-rheumatic drugs and more recently biologics as immune modulatory agents. The purpose of this article is to identify the role of new treatment approaches focusing on small molecules as therapeutic option in uveitis. Areas covered: A MEDLINE database search was conducted through February 2017 using the terms 'uveitis' and 'small molecule'...
August 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28731127/pidotimod-exacerbates-allergic-pulmonary-infection-in-an-ova-mouse-model-of-asthma
#2
Luo-Qin Fu, Ya-Li Li, Ai-Kun Fu, Yan-Ping Wu, Yuan-Yuan Wang, Sheng-Lan Hu, Wei-Fen Li
Pidotimod is a synthetic dipeptide with biological and immuno‑modulatory properties. It has been widely used for treatment and prevention of recurrent respiratory infections. However, its impact on the regulation of allergic pulmonary inflammation is still not clear. In the current study, an ovalbumin (OVA)‑induced allergic asthma model was used to investigate the immune‑modulating effects of pidotimod on airway eosinophilia, mucus metaplasia and inflammatory factor expression compared with dexamethasone (positive control)...
July 21, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28724427/curcumin-the-spicy-modulator-of-breast-carcinogenesis
#3
REVIEW
Urmila Banik, Subramani Parasuraman, Arun Kumar Adhikary, Nor Hayati Othman
Worldwide breast cancer is the most common cancer in women. For many years clinicians and the researchers are examining and exploring various therapeutic modalities for breast cancer. Yet the disease has remained unconquered and the quest for cure is still going on. Present-day strategy of breast cancer therapy and prevention is either combination of a number of drugs or a drug that modulates multiple targets. In this regard natural products are now becoming significant options. Curcumin exemplifies a promising natural anticancer agent for this purpose...
July 19, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/28718997/mesenchymal-stem-cell-derived-factors-immuno-modulatory-effects-and-therapeutic-potential
#4
REVIEW
Vladislav Volarevic, Marina Gazdic, Bojana Simovic Markovic, Nemanja Jovicic, Valentin Djonov, Nebojsa Arsenijevic
Stem cell-based therapy is considered to be a new hope in transplantation medicine. Among stem cells, mesenchymal stem cells (MSCs) are, due to their differentiation and immuno-modulatory characteristics, the most commonly used as therapeutic agents in the treatment of immune-mediated diseases. MSCs migrate to the site of inflammation and modulate immune response. The capacity of MSC to alter phenotype and function of immune cells are largely due to the production of soluble factors which expression varies depending on the pathologic condition to which MSCs are exposed...
July 18, 2017: BioFactors
https://www.readbyqxmd.com/read/28643902/modulation-of-antitumor-immunity-contributes-to-the-enhanced-therapeutic-efficacy-of-liposomal-oxaliplatin-in-mouse-model
#5
Taro Shimizu, Amr S Abu Lila, Miho Nishio, Yusuke Doi, Hidenori Ando, Masami Ukawa, Yu Ishima, Tatsuhiro Ishida
Immune modulation of the tumor microenvironment has been reported to participate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we reported that liposomal encapsulation of oxaliplatin (l-OHP) within PEGylated liposomes conferred a superior antitumor efficacy to free l-OHP in murine colorectal carcinoma-bearing mice through permitting preferential accumulation of the encapsulated drug within tumor tissue. However, the contribution of the immune-modulatory properties of liposomal l-OHP and/or free l-OHP to the overall antitumor efficacy was not elucidated...
June 23, 2017: Cancer Science
https://www.readbyqxmd.com/read/28589127/function-and-therapeutic-potential-of-mesenchymal-stem-cells-in-atherosclerosis
#6
REVIEW
Feifei Li, Xia Guo, Shi-You Chen
Atherosclerosis is a complicated disorder and largely attributable to dyslipidaemia and chronic inflammation. Despite therapeutic advances over past decades, atherosclerosis remains the leading cause of mortality worldwide. Due to their capability of immunomodulation and tissue regeneration, mesenchymal stem cells (MSCs) have evolved as an attractive therapeutic agent in various diseases including atherosclerosis. Accumulating evidences support the protective role of MSCs in all stages of atherosclerosis. In this review, we highlight the current understanding of MSCs including their characteristics such as molecular markers, tissue distribution, migratory property, immune-modulatory competence, etc...
2017: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28567588/immunotherapy-and-radiation-in-glioblastoma
#7
REVIEW
Solmaz Sahebjam, Andrew Sharabi, Michael Lim, Pravin Kesarwani, Prakash Chinnaiyan
Radiation therapy plays a central role in the management of glioblastoma. Although primarily thought of as modality to provide local tumor control through DNA damage, the capacity of ionizing radiation to modulate tumor immune response has long been recognized. The recent emergence of clinically active immunotherapies offers exciting potential for harnessing the immune modulatory effects or radiation through combinatorial strategies designed to enhance clinical outcomes. In this Review, we provide background describing the unique immune environment within the central nervous system, how ionizing radiation may modulate the tumor immune response, preclinical and clinical data testing the combination of radiation and immune modulating agents, and highlight some of the current challenges in extending these findings clinically...
May 31, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28510090/the-melatonin-immunomodulatory-actions-in-radiotherapy
#8
REVIEW
M Najafi, A Shirazi, E Motevaseli, Gh Geraily, F Norouzi, M Heidari, S Rezapoor
Radiotherapy has a key role in cancer treatment in more than half of patients with cancer. The management of severe side effects of this treatment modality is a limiting factor to appropriate treatment. Immune system responses play a pivotal role in many of the early and late side effects of radiation. Moreover, immune cells have a significant role in tumor response to radiotherapy, such as angiogenesis and tumor growth. Melatonin as a potent antioxidant has shown appropriate immune regulatory properties that may ameliorate toxicity induced by radiation in various organs...
April 2017: Biophysical Reviews
https://www.readbyqxmd.com/read/28506000/therapeutic-effects-of-oral-dimethyl-fumarate-on-stroke-induced-by-middle-cerebral-artery-occlusion-an-animal-experimental-study
#9
Anahid Safari, Mehdi Fazeli, Mohammad Reza Namavar, Nader Tanideh, Peyman Jafari, Afshin Borhani-Haghighi
BACKGROUND: Dimethyl fumarate (DMF) has immune-modulatory and neuro-protective characteristics that can be used for treatment of acute ischemic stroke. OBJECTIVE: To investigate the therapeutic effects of DMF on histological and functional recovery of rats after transient middle cerebral artery (MCA) occlusion. METHODS: 22 Sprague-Dawley male rats weighing 275-300 g were randomized into three groups by block randomization. In the sham group (n = 7), the neck was opened, but neither MCA was occluded, nor any drug was administered...
2017: Restorative Neurology and Neuroscience
https://www.readbyqxmd.com/read/28461396/pembrolizumab-pomalidomide-and-low-dose-dexamethasone-for-relapsed-refractory-multiple-myeloma
#10
Ashraf Badros, Elizabeth Hyjek, Ning Ma, Alexander Lesokhin, Ahmet Dogan, Aaron P Rapoport, Mehmet Kocoglu, Emily Lederer, Sunita Philip, Todd Milliron, Cameron Dell, Olga Goloubeva, Zeba Singh
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance anti-myeloma cellular immunity generated by pomalidomide leading to improved clinical responses. In this single-center, phase II study, 48 patients with relapsed/refractory MM (RRMM) received 28-days cycles of pembrolizumab, 200 mg intravenously every 2 weeks, pomalidomide 4 mg daily for 21 days and dexamethasone 40 mg weekly. Patients had a median of 3 (range: 2-5) lines of therapy, median age 64 (range: 35-83) years and had received both immune modulatory agent and proteasome inhibitor; (35 [73%] of 48) were refractory to both; (31 [70%]) had received an autologous transplant and (30 [62%]) had high-risk cytogenetics...
May 1, 2017: Blood
https://www.readbyqxmd.com/read/28461106/effector-and-regulatory-b-cells-in-multiple-sclerosis
#11
Elsebeth Staun-Ram, Ariel Miller
The role of B cells in the pathogenesis of Multiple Sclerosis (MS), an autoimmune neurodegenerative disease, is becoming eminent in recent years, but the specific contribution of the distinct B cell subsets remains to be elucidated. Several B cell subsets have shown regulatory, anti-inflammatory capacities in response to stimuli in vitro, as well as in the animal model of MS: Experimental Autoimmune Encephalomyelitis (EAE). However, the functional role of the B regulatory cells (Bregs) in vivo and specifically in the human disease is yet to be clarified...
April 28, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28388572/combination-gitr-targeting-pd-1-blockade-with-vaccination-drives-robust-antigen-specific-antitumor-immunity
#12
Daniel O Villarreal, Diana Chin, Melissa A Smith, Leopoldo L Luistro, Linda A Snyder
Tumor progression is facilitated immunologically by mechanisms that include low antigen expression, an absence of coimmunostimulatory signals, and the presence of regulatory T cells (Tregs), all of which act to suppress and restrict effector T cells in the tumor. It may be possible to overcome these conditions by a combination of modulatory immunotherapy agents and tumor-antigen targeting to activate and drive effective antitumor T cell responses. Here, we demonstrated that co-administration of aGITR and aPD-1 monoclonal antibodies (mAb) in combination with a peptide vaccine (Vax) in mice bearing established tumors significantly delayed tumor growth and induced complete regression in 50% of the mice...
June 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28347310/a-novel-in-vitro-model-reveals-distinctive-modulatory-roles-of-plasmodium-falciparum-and-plasmodium-vivax-on-na%C3%A3-ve-cell-mediated-immunity
#13
Setthakit Chitsanoor, Sangdao Somsri, Panyu Panburana, Mathirut Mungthin, Ratawan Ubalee, Maliwan Emyeam, Somchai Jongwutiwes, Jetsumon Sattabongkot, Rachanee Udomsangpetch
BACKGROUND: To date, human peripheral blood mononuclear cells (PBMCs) have been used mainly in immune stimulation assays and the interpretation of data can be influenced by the previous immunological history of donors and cross reactivity with other infectious agents. Resolving these limitations requires an alternative in vitro model to uncover the primary response profiles. METHODS: A novel in vitro model of mononuclear cells (MNCs) generated from haematopoietic stem cells (HSCs) was developed and these cells were then co-cultured with various antigens from Plasmodium falciparum and Plasmodium vivax to investigate the response of naïve immune cells to malaria antigens by flow cytometry...
March 27, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28274138/role-of-interferon-in-melanoma-old-hopes-and-new-perspectives
#14
REVIEW
Martina Sanlorenzo, Igor Vujic, Fabrizio Carnevale-Schianca, Pietro Quaglino, Loretta Gammaitoni, Maria Teresa Fierro, Massimo Aglietta, Dario Sangiolo
Interferons (IFNs) play a key role in modulating anti-microbial and antitumor immune responses. In oncology, past attempts to exploit IFNs therapeutically did not fulfill expectations, and had only modest clinical results, mostly limited to adjuvant melanoma treatment. The recent successes of immunotherapy in oncology have brought new attention to the potential of immune-modulatory agents like the IFNs. Areas covered: The authors review the biological effects of IFN on melanoma and immune cells. Then, the authors summarize the clinical results of adjuvant and therapeutic IFN in melanoma, giving focus to possible prognostic factors and new on-going clinical trials...
April 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28260909/update-on-targeted-therapies-for-advanced-non-small-cell-lung-cancer-nivolumab-in-context
#15
REVIEW
Alexander D Le, Saeed K Alzghari, Gary W Jean, Ninh M La-Beck
While the initial treatment of non-small cell lung cancer (NSCLC) usually relies on surgical resection followed by systemic cytotoxic chemotherapy and/or radiation therapy, recent advances in understanding of NSCLC biology and immunology have spurred the development of numerous targeted therapies. In particular, a class of immune modulatory drugs targeting the immune checkpoint pathways has demonstrated remarkable durable remissions in a select minority of advanced NSCLC patients, potentially heralding the elusive "cancer cure"...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28182964/dietary-flavonoids-and-modulation-of-natural-killer-cells-implications-in-malignant-and-viral-diseases
#16
REVIEW
Markus Burkard, Christian Leischner, Ulrich M Lauer, Christian Busch, Sascha Venturelli, Jan Frank
Flavonoids are a large group of secondary plant metabolites present in the diet with numerous potentially health-beneficial biological activities. In addition to antioxidant, anti-inflammatory, cholesterol-lowering, and many other biological functions reported in the literature, flavonoids appear to inhibit cancer cell proliferation and stimulate immune function. Although the immunomodulatory potential of flavonoids has been intensively investigated, only little is known about their impact on natural killer (NK) cells...
January 24, 2017: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/28079913/intravenous-immunoglobulin-in-the-treatment-of-hematologic-disorders-in-pediatrics
#17
Gabriela Villanueva, Jill L O de Jong, Jennifer L McNeer
Intravenous immunoglobulin (IVIG) is pooled immunoglobulin G derived from human blood donors. It was introduced in the early 1980s to treat immunodeficiency disorders. Since then, its use has expanded to other fields such as neurology, rheumatology, and hematology. IVIG has been used to provide passive immunity in qualitative and quantitative immunoglobulin disorders, to neutralize antibodies in immune-mediated diseases, and as an immune modulatory agent. The difficulty of producing IVIG in high quantities, in addition to a growing list of "off-label" indications, has resulted in a worldwide shortage and increase in cost...
January 1, 2017: Pediatric Annals
https://www.readbyqxmd.com/read/28079912/intravenous-immunoglobulin-in-the-treatment-of-primary-immunodeficiency-diseases
#18
Deirdre De Ranieri, Nana Sarkoah Fenny
Intravenous immunoglobulin (IVIG) has been used as antibody replacement therapy in primary immunodeficiency diseases (PIDDs) for more than 50 years. Its role as a therapeutic agent has expanded over the past couple of decades as its anti-inflammatory and immune-modulatory mechanisms of action have been elucidated. It is now used "off-label" to treat other autoimmune diseases. This article focuses on the role of IVIG in the treatment of PIDDs characterized by absent or deficient antibody production. Replacement doses are given on a monthly basis in these conditions as a prophylactic measure to prevent acute and serious bacterial infections...
January 1, 2017: Pediatric Annals
https://www.readbyqxmd.com/read/28045749/histologic-assessment-of-lichenoid-dermatitis-observed-in-patients-with-advanced-malignancies-on-antiprogramed-cell-death-1-anti-pd-1-therapy-with-or-without-ipilimumab
#19
Shaun Chou, Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, Pablo Fernandez-Penas
Lichenoid drug reaction is a common adverse reaction in patients taking immune-modulatory agents such as antiprogramed cell death (PD-1) and cytotoxic T lymphocyte antigen-4 agents. The authors describe the clinical and histologic features of lichenoid drug reaction in 20 biopsies from 15 patients on anti-PD-1 agents and 9 biopsies from 7 patients on anti-PD-1 plus ipilimumab therapy. Clinically, all except 2 patients presented with discrete, violaceous exanthematous papules to plaques. The lichenoid inflammation in the majority (18 of 29 biopsies) was florid although histology was quite heterogeneous...
January 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/27929422/co-administration-of-lipid-nanoparticles-and-sub-unit-vaccine-antigens-is-required-for-increase-in-antigen-specific-immune-responses-in-mice
#20
Elizabeth A Thoryk, Gokul Swaminathan, Steven Meschino, Kara S Cox, Marian Gindy, Danilo R Casimiro, Andrew J Bett
A vast body of evidence suggests that nanoparticles function as potent immune-modulatory agents. We have previously shown that Merck proprietary Lipid NanoParticles (LNPs) markedly boost B-cell and T-cell responses to sub-unit vaccine antigens in mice. To further evaluate the specifics of vaccine delivery and dosing regimens in vivo, we performed immunogenicity studies in BALB/c and C57BL/6 mice using two model antigens, Hepatitis B Surface Antigen (HBsAg) and Ovalbumin (OVA), respectively. To assess the requirement for co-administration of antigen and LNP for the elicitation of immune responses, we evaluated immune responses after administering antigen and LNP to separate limbs, or administering antigen and LNP to the same limb but separated by 24 h...
December 6, 2016: Vaccines
keyword
keyword
55779
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"